Yassin Abdelghaffar Charity Center for Liver Disease and Research
Quick facts
Marketed products
- Combined therapy LDV and SOF · Virology / Hepatology
LDV (ledipasvir) and SOF (sofosbuvir) are direct-acting antivirals that inhibit hepatitis C virus NS5A and NS5B polymerase, respectively, blocking viral replication.
Phase 3 pipeline
- Combined Therapy SOF and DCV · Virology / Hepatology
This combination therapy uses sofosbuvir (a nucleotide polymerase inhibitor) and daclatasvir (an NS5A inhibitor) to block hepatitis C virus replication through dual inhibition of viral enzymes.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Yassin Abdelghaffar Charity Center for Liver Disease and Research portfolio CI brief
- Yassin Abdelghaffar Charity Center for Liver Disease and Research pipeline updates RSS
Frequently asked questions about Yassin Abdelghaffar Charity Center for Liver Disease and Research
What are Yassin Abdelghaffar Charity Center for Liver Disease and Research's marketed drugs?
Top marketed products include Combined therapy LDV and SOF.
What is Yassin Abdelghaffar Charity Center for Liver Disease and Research's pipeline?
Yassin Abdelghaffar Charity Center for Liver Disease and Research has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Combined Therapy SOF and DCV.
Related
- Combined therapy LDV and SOF · Virology / Hepatology
- Sector hub: All tracked pharma companies